RU2348418C2 - Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей - Google Patents

Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей Download PDF

Info

Publication number
RU2348418C2
RU2348418C2 RU2005121256/14A RU2005121256A RU2348418C2 RU 2348418 C2 RU2348418 C2 RU 2348418C2 RU 2005121256/14 A RU2005121256/14 A RU 2005121256/14A RU 2005121256 A RU2005121256 A RU 2005121256A RU 2348418 C2 RU2348418 C2 RU 2348418C2
Authority
RU
Russia
Prior art keywords
tumor
dendritic cells
cells
partially matured
bcg
Prior art date
Application number
RU2005121256/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2005121256A (ru
Inventor
Марникс Л. БОШ (US)
Марникс Л. БОШ
Original Assignee
Норсуэст Байотерапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Норсуэст Байотерапьютикс, Инк. filed Critical Норсуэст Байотерапьютикс, Инк.
Publication of RU2005121256A publication Critical patent/RU2005121256A/ru
Application granted granted Critical
Publication of RU2348418C2 publication Critical patent/RU2348418C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2005121256/14A 2002-12-06 2003-12-05 Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей RU2348418C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06
US60/431,267 2002-12-06

Publications (2)

Publication Number Publication Date
RU2005121256A RU2005121256A (ru) 2006-02-10
RU2348418C2 true RU2348418C2 (ru) 2009-03-10

Family

ID=32507696

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005121256/14A RU2348418C2 (ru) 2002-12-06 2003-12-05 Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей

Country Status (18)

Country Link
US (2) US20060057120A1 (https=)
EP (2) EP1567155B1 (https=)
JP (2) JP4859169B2 (https=)
KR (1) KR101144196B1 (https=)
CN (2) CN102600461B (https=)
AT (1) ATE486125T1 (https=)
AU (2) AU2003293411B2 (https=)
BR (1) BRPI0317064B8 (https=)
CA (1) CA2509058A1 (https=)
DE (1) DE60334725D1 (https=)
DK (1) DK1567155T3 (https=)
ES (1) ES2354944T3 (https=)
IL (1) IL169002A (https=)
MX (1) MXPA05006042A (https=)
PL (1) PL377209A1 (https=)
PT (1) PT1567155E (https=)
RU (1) RU2348418C2 (https=)
WO (1) WO2004053072A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013147642A1 (ru) * 2012-03-29 2013-10-03 Egorov Oleg Borisovich Способ противоопухолевой иммунотерапии
RU2565542C2 (ru) * 2010-02-10 2015-10-20 Иммуникум Аб Улучшенная композиция для ингибирования пролиферации опухолевых клеток
RU2610427C2 (ru) * 2009-07-09 2017-02-10 Тихеникс С.А. Способы и композиции для применения в клеточной терапии
RU2733886C2 (ru) * 2016-06-07 2020-10-07 Куратис Инк. КОМПОЗИЦИЯ ДЛЯ СТИМУЛИРОВАНИЯ СОЗРЕВАНИЯ ДЕНДРИТНЫХ КЛЕТОК, СОДЕРЖАЩАЯ ГИБРИДНЫЙ БЕЛОК Rv2299c/ESAT-6
RU2749610C2 (ru) * 2015-09-15 2021-06-16 Нортвест Байотерапьютикс, Инк. Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8420078B2 (en) * 2005-03-10 2013-04-16 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (en) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Mature dendritic cells loaded with tumor polylysates and antitumoral vaccine base thereon
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
RU2361598C1 (ru) * 2008-02-18 2009-07-20 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, индуцирующее созревание дендритных клеток
CA2718438C (en) * 2008-03-27 2021-06-29 Geron Corporation Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
RU2575978C2 (ru) * 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
US8961957B2 (en) 2012-06-27 2015-02-24 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
IL256522B2 (en) 2015-06-30 2024-10-01 Northwest Biotherapeutics Inc Optimally activated dendritic cells that result in an enhanced or enhanced antitumor immune response
US12059434B2 (en) 2017-02-28 2024-08-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated DC1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
CN116637180A (zh) * 2022-02-15 2023-08-25 沈阳药科大学 萜类化合物在提高其淋巴靶向作用中的应用
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
WO2000047719A2 (en) * 1999-02-11 2000-08-17 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6274378B1 (en) * 1997-10-27 2001-08-14 The Rockefeller University Methods and compositions for obtaining mature dendritic cells
WO2001087325A1 (en) * 2000-05-12 2001-11-22 Northwest Biotherapeutics, Inc. Method to increase class i presentation of exogenous antigens by human dendritic cells
WO2002040646A1 (en) * 2000-11-14 2002-05-23 Universite Libre De Bruxelles Generation and use of dendritic cells
RU2000119729A (ru) * 1997-12-23 2002-08-20 Джинезис Рисеч Энд Девелопмент Корпорейшн Лимитед Композиции, полученные из mycobacterium vaccae и способы их использования

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CA2343355A1 (en) * 1998-09-15 2000-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education In situ injection of antigen-presenting cells with genetically enhanced cytokine expression
EP1126023A4 (en) * 1998-10-02 2005-02-16 Mitsubishi Chem Corp METHOD FOR THE INDUCTION OF CELLULAR IMMUNITY AND CELLS WITH INDUCED CELLULAR IMMUNITY
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
CN1367688A (zh) * 1999-04-14 2002-09-04 美国政府卫生与公众服务部 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物
AU2403901A (en) * 1999-12-28 2001-07-09 Ichiro Azuma Maturation-promoting agent for immature dendritic cells
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
CA2459713C (en) * 2001-09-06 2015-08-18 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
RU2364625C2 (ru) * 2003-02-27 2009-08-20 Норсуэст Байотерапьютикс, Инк. Генерирование дендритных клеток из моноцитарных предшественников дендритных клеток с помощью gm-csf в отсутствие дополнительных цитокинов

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US6274378B1 (en) * 1997-10-27 2001-08-14 The Rockefeller University Methods and compositions for obtaining mature dendritic cells
RU2000119729A (ru) * 1997-12-23 2002-08-20 Джинезис Рисеч Энд Девелопмент Корпорейшн Лимитед Композиции, полученные из mycobacterium vaccae и способы их использования
WO2000047719A2 (en) * 1999-02-11 2000-08-17 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
WO2001087325A1 (en) * 2000-05-12 2001-11-22 Northwest Biotherapeutics, Inc. Method to increase class i presentation of exogenous antigens by human dendritic cells
WO2002040646A1 (en) * 2000-11-14 2002-05-23 Universite Libre De Bruxelles Generation and use of dendritic cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KADOWAKI et al. Distinct CpG DNA and polyinosinic-polycytidilic acid double steanded RNA, respectively stimulate CD11c-type 2 dendritic cell precursors and CD11+ dendritic cells to produce type I IFN // The Jour, of Immunology. 2001, vol.166(4), с 2291-2295. TJOA et al. Dendritic cell-based immunotherapy for prostate cancer // CA Cancer J. Clin. 1999, vol.49, с 117-128. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2610427C2 (ru) * 2009-07-09 2017-02-10 Тихеникс С.А. Способы и композиции для применения в клеточной терапии
RU2565542C2 (ru) * 2010-02-10 2015-10-20 Иммуникум Аб Улучшенная композиция для ингибирования пролиферации опухолевых клеток
WO2013147642A1 (ru) * 2012-03-29 2013-10-03 Egorov Oleg Borisovich Способ противоопухолевой иммунотерапии
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
RU2749610C2 (ru) * 2015-09-15 2021-06-16 Нортвест Байотерапьютикс, Инк. Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком
RU2733886C2 (ru) * 2016-06-07 2020-10-07 Куратис Инк. КОМПОЗИЦИЯ ДЛЯ СТИМУЛИРОВАНИЯ СОЗРЕВАНИЯ ДЕНДРИТНЫХ КЛЕТОК, СОДЕРЖАЩАЯ ГИБРИДНЫЙ БЕЛОК Rv2299c/ESAT-6

Also Published As

Publication number Publication date
KR20050084189A (ko) 2005-08-26
KR101144196B1 (ko) 2012-05-21
JP2006510667A (ja) 2006-03-30
EP1567155A2 (en) 2005-08-31
ES2354944T3 (es) 2011-03-21
WO2004053072A2 (en) 2004-06-24
JP4859169B2 (ja) 2012-01-25
AU2011200352B2 (en) 2013-06-27
US20120251561A1 (en) 2012-10-04
EP2260861A1 (en) 2010-12-15
BRPI0317064B1 (pt) 2020-11-03
CA2509058A1 (en) 2004-06-24
RU2005121256A (ru) 2006-02-10
CN102600461B (zh) 2017-07-14
MXPA05006042A (es) 2005-09-21
AU2003293411A1 (en) 2004-06-30
HK1082180A1 (en) 2006-06-02
DE60334725D1 (de) 2010-12-09
BR0317064A (pt) 2005-10-25
CN1738619B (zh) 2012-04-18
EP1567155A4 (en) 2006-12-13
US20060057120A1 (en) 2006-03-16
PT1567155E (pt) 2011-01-28
CN102600461A (zh) 2012-07-25
AU2003293411B2 (en) 2010-10-28
AU2011200352A1 (en) 2011-02-17
JP2011246493A (ja) 2011-12-08
IL169002A (en) 2015-01-29
BRPI0317064B8 (pt) 2021-05-25
DK1567155T3 (da) 2011-02-14
WO2004053072A3 (en) 2005-06-16
ATE486125T1 (de) 2010-11-15
PL377209A1 (pl) 2006-01-23
EP1567155B1 (en) 2010-10-27
CN1738619A (zh) 2006-02-22
JP5707284B2 (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
RU2348418C2 (ru) Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей
JP2006510667A5 (https=)
AU2023202977B2 (en) Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
AU2018260971B2 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
AU2013234394B2 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
HK40128538A (en) Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
HK1082180B (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
HK1151249A (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20111206

NF4A Reinstatement of patent

Effective date: 20121120

MM4A The patent is invalid due to non-payment of fees

Effective date: 20161206

NF4A Reinstatement of patent

Effective date: 20170821